Class Action Suit Filed Over Plavix Risks And Benefits
This article was originally published in The Pink Sheet Daily
Lawsuit alleges that Bristol and Sanofi "duped" payers into paying for prescriptions of the anti-coagulant.
You may also be interested in...
Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.
Overall study group, however, did not show reduction in risk in combined rate of death, heart attack or stroke from combination therapy of Plavix and low-dose aspirin.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.